MONMOUTH JUNCTION, N.J., Jan. 21, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, today announced that Dr. Volker Humbert, M.D. has joined the company as Senior Manager of Clinical Affairs.
Dr. Humbert, anesthesiologist and intensivist, joined CytoSorbents from PULSION Medical Systems, a leader in critical care hemodynamic monitoring which was acquired by Maquet Medical Systems AG, a subsidiary of Getinge Group, in 2014. “It is great to join CytoSorbents’ very dynamic and competent team,” said Dr. Humbert. “With my clinical knowledge and experience from my years as a Medical Director for Pulsion, I look forward to strengthening the medical expertise of the company and providing comprehensive medical support and education to medical professionals worldwide using CytoSorb® to help patients. I truly believe that CytoSorb® has huge potential and can change critical care medicine fundamentally.”
Dr. Humbert has as an extensive leadership career in critical care and emergency medicine, treating critically-ill patients in the intensive care unit, providing surgical anesthesia during cardiac surgery, and managing patients post-operatively. His diverse set of skills and expertise also includes regulatory affairs, medical advisory board management, product safety monitoring, sales, marketing training and support, medical consulting, and project management. Dr. Humbert received his academic and doctoral degrees from Ludwigs-Maximilians University of Munich, received specialist training in both critical care and emergency medicine at Hospital Munich-Bogenhausen, is certified as a specialist in intensive care medicine and anesthesia by the Bavarian Medical Association in Munich, Germany, served as an emergency physician for the Austrian Red Cross, and completed coursework for medical engineering at the University of Keiserslautern.
“We are very fortunate to add Dr. Humbert as a member of the CytoSorbents team,” said Dr. Phillip Chan, CEO of CytoSorbents. “As we continue to expand the global footprint of CytoSorb® in both critical care medicine and cardiac surgery, his wealth of clinical and industry expertise is a perfect fit to help strengthen communication, awareness, and education amongst physicians and healthcare professionals across all of our sales territories. We are confident that Dr. Humbert will have an immediate and long-term impact in accelerating usage, adoption, and sales of CytoSorb®.”
About CytoSorbents Corporation
CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 9,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s websites: https://cytosorbents.com and http://www.cytosorb.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(732) 329-8885 ext. *825
The Ruth Group
Public Relations Contact:
The Ruth Group
SOURCE CytoSorbents Corporation